International Summer School on Immuno-Oncology: emerging targets and combination therapies

Objectives

The "Summer School of Immuno-Oncology: Emerging targets and combination therapies" aims to discuss knowledge and recent advances in the field of cancer immunotherapy. A panel of national and international lecturers will cover various aspects of preclinical and clinical immuno-oncology, ranging from the study of basic pathogenetic mechanisms for the discovery of new immunotherapeutic targets to more clinical aspects related to the effectiveness of combinatorial approaches in boosting cancer immunotherapy. The school will provide young oncologists, PhDs and PhD students, involved in clinical and research projects related to cancer immunotherapy, with a solid background in novel immuno-oncology topics. In particular, we will focus on issues related to: inflammation and cancer; the immunity-cancer interface: mutational load of the tumor and editing of immune responses; myelopoietic alterations, tumor microenvironment and anticancer immunotherapy; radioimmunotherapy and immunotherapy of blood cancers; clinical immunotherapy; antiviral response of the host and cancer development; role of immunosenescence and inflammaging in neoplasms; and immunological disorders and cancer. Furthermore, advanced knowledge on statistics will be provided for the analysis of preclinical and clinical data. The goal is to discuss the current state of knowledge in the field of cancer immunotherapy from an interdisciplinary and translational “bench-to-bedside” standpoint.

Addressed to

Physicians and Resident doctors in oncology, clinical immunology and allergology, hematology, microbiology and virology, radiotherapy; Biologists, Pharmacists, but also PhD students, students and graduates of the degree programme in Pharmaceutical Chemistry and Technology and Biotechnology.

It won’t be possible to give credits to physicians specialized in different fields.

Access mode

To ensure compliance with the health provisions regarding Covid 19, the meeting will be held both as an in-class course and as a live webinar.

The in-class course will take place at the venue specified underneath. Please note that due to COVID mitigation measures, Only a limited number of attendees will be accepted.

The LIVE Webinar will allow participants to attend the meeting from remote.

When registering, it is necessary to select the desired participation mode (in-class or remote). Registration for the activity can only take place online, no registrations will be accepted at the meeting venue.

Participants who decide to follow the LIVE webinar, will need a good Internet connection and a device (PC, Smartphone, Tablet) capable of running an updated Internet browser (e.g. Chrome or Firefox).

AccMed will organize the event exclusively in digital mode in case of worsening of the current COVID-19 emergency. In this case, AccMed will inform speakers and participants.

The official language of the course is English. No simultaneous translation will be provided.

CME In-Class Course

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-325502): 24 CME points.

The credit certification is subject to:

• Professions/specializations should correspond to those which have been accredited for CME;
• Professions/specializations should correspond to those which have been accredited for CME
• attendance at the 100% of the event
• the completion of the Meeting evaluation online form;
• completion of the final test (at least 75% of correct answers). 1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

CME Webinar live

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-325681): 36 CME points.

The credit certification is subject to:

• Professions/specializations should correspond to those which have been accredited for CME;
• Professions/specializations should correspond to those which have been accredited for CME
• attendance at the live webinar on the platform https://fad.accmed.org;
• the completion of the Meeting evaluation online form;
• completion of the final test (at least 75% of correct answers). 5 attempts admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

Program

Monday, 30^th August

10.00

Registration and welcome coffee

10.30

Opening Address
Gian Carlo Avanzi, Marco Krengli

11.00

Introduction to the school and programme presentation
Marisa Gariglio, Alessandra Gennari, Antonio Sica

11.30

Opening Lecture: Cancer and Inflammation
Alberto Mantovani
Chairmen: Gian Carlo Avanzi, Antonio Sica

12.30

Lunch break

 

AFTERNOON SESSION: The cancer-immune system interface

Chairmen: Gianluca Aimaretti, Ciro Isidoro

14.00

Tumor mutational load and cancer therapy
Giovanni Germano

14.45

Targeting adaptive immunity in cancer
Enrico Lugli

15.30

Coffee break

16.00

Professional antigen presenting cells/DC in cancer
Silvano Sozzani

16.45

Immune checkpoints in cancer therapy
Andrea Anichini

17.30

Discussion
Facilitator: Antonio Sica

18.00

Adjourn

Tuesday, 31^st August

 

MORNING SESSION: Anticancer immunotherapies: pros and cons

Chairmen: Umberto Dianzani, Antonia Follenzi

8.40

Lecture: Update on anticancer immunotherapies
Paolo Antonio Ascierto

9.40

Extracellular Matrix at the cross-road between cancer and immunity
Mario Colombo

10.00

Tumor microenvironment and emergency hematopoiesis
Laura Strauss

10.30

Coffee Break

11.00

Suppressor myeloid cells in cancer
Vincenzo Bronte

11.30

NK in cancer therapy
Angela Santoni

12.00

Discussion Q&A
Facilitator: Gianluca Gaidano

12.30

Giovanni Melillo interviewed by Pier Luigi Canonico (NO CME)

13.00

Lunch Break

 

AFTERNOON SESSION: Hemato & Radio Immunotherapy

Chairmen: Marco Krengli, Andrea Riccardo Filippi

14.30

Radiotherapy and immunotherapy: current knowledge of a clinical partnership
Pierfrancesco Franco

15.00

Radiotherapy effects on tumor micro-environment
Andrea Riccardo Filippi

15.30

SBRT and immunotherapy, a winning partnership?
Davide Franceschini

15.50

Coffee Break

 

AFTERNOON SESSION: Hemato & Radio Immunotherapy

Chairmen: Gianluca Gaidano, Giovanni Martinelli

16.20

Molecular determinants of immune-response
Massimo Dominici

16.40

Immune checkpoints inhibitors in liquid tumors
Gianluca Gaidano

17.10

CAR-T cells
Marco Ladetto

17.30

Discussion Q&A
Facilitator: Giovanni Martinelli

18.15

CME Session Adjourn

18.30

Cocktail with the statisticians – (NO CME)
Chairmen: Paolo Bruzzi, Fabrizio Faggiano, Giovanni Melillo

Innovative trial design – Adaptive Immunotherapy Trials Oriana Nanni, Valter Torri (15 min)
Endpoints & Summary Indicators in Immunotherapy Trials Paolo Bruzzi (15 min)

Wednesday, 1^st September

 

MORNING SESSION: Immunotherapy in the Clinic

Chairmen: Pier Luigi Canonico, Alessandra Gennari

9.00

Lecture: Regulatory Process and clinical benefit
Armando Genazzani

09.40

IO & Lung Cancer
Silvia Novello

10.00

IO & Urology
Matteo Bellone

10.20

Immunotherapy of Melanoma: what we already know and future perspectives
Michele Del Vecchio

10.40

Coffee Break

11.00

Breast Cancer: evolution of innovative agents from CDK 4/6 to checkpoint inhibitors
Valentina Guarneri

11.20

IO & Hepatocellular carcinoma
David J. Pinato

11.40

Innovative IO therapies in solid tumors: CAR-T, oncolytic viruses and beyond
Giuseppe Curigliano

12.15

Antiandrogenic therapy in prostate cancer and COVID
Andrea Alimonti

12.30

Discussion Q&A
Facilitator: Alessandra Gennari

13.00

Lunch Break

 

AFTERNOON SESSION: The complex interplay between SARS-CoV-2 and the host immune response

Chairmen: Marisa Gariglio, Santo Landolfo

14.30

Vaccines and monoclonals to regain our freedom
Rino Rappuoli

15.10

SARS COV2 variants
Nicole Fischer

15.50

Innate RNA sensing of SARS-CoV2 and strategies of viral evasion
John Hiscott

16.30

Coffee Break

17.00

The cGAS-STING pathway in COVID-19 – protective and pathogenic potential
Soren Paludan

17.40

Discussion Q&A
Facilitator: Marco De Andrea

18.00

Adjourn

Thursday, 2^nd September

 

MORNING SESSION: Immunosenescence, Inflammaging and Cancer

Chairmen: Lia Rimondini, Annalisa Chiocchetti

9.00

Inflammaging and Cancer
Massimiliano Bonafè

9.50

Common mechanisms of age-related diseases: implication for disease-specific biomarkers identification
Fabiola Olivieri

10.40

Coffee Break

11.10

Genetics and Epigenetics of Aging
Paolo Garagnani

12.00

Discussion Q&A
Facilitator: Ciro Isidoro

12.30

Lunch Break

 

AFTERNOON SESSION: Immunological disorders and cancer prognosis and therapy

Chairmen: Claudio Santoro, Mario Pirisi

14.00

Allergy/autoimmunity and cancer
Marinos Kallikourdis

14.50

Microbioma, immunity and cancer
Maria Rescigno

15.10

Tertiary lymphoid structures in immunology and immunotherapy
Catherine Fridman

15.30

Discussion Q&A
Facilitator: Antonio Sica

16.00

Closing Lecture: B cells and antibodies, the next challenge in immunotherapy
Wolf Fridman

16.30

Adjournment and final evaluation questionnaire
Marisa Gariglio, Alessandra Gennari, Antonio Sica